Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC

Share this content:
MEK inhibition with cobimetinib may improve the response rate with checkpoint inhibition.
MEK inhibition with cobimetinib may improve the response rate with checkpoint inhibition.
The following article features coverage from the 2018 Gastrointestinal Cancers Symposium. Click here to read more of Cancer Therapy Advisor's conference coverage.

Atezolizumab with cobimetinib may yield a partial response in some patients with heavily pre-treated metastatic colorectal cancer (CRC), according to research being presented at the 2018 Gastrointestinal Cancers Symposium in San Francisco, California.1

Microsatellite stability (MSS), a common feature of CRC, is linked to a poor response to PD-1/PD-L1 inhibition. MEK inhibition with cobimetinib may, however, improve the response rate to checkpoint inhibition.

For this phase 1b study (ClinicalTrials.gov Identifier: NCT01988896), researchers evaluated the safety and efficacy of atezolizumab, a PD-L1 inhibitor, with cobimetinib for patients with heavily pre-treated metastatic CRC.

Of 84 enrolled patients, 66 had received at least 5 prior therapies; 29 had MSS, 8 had low MS instability, and 1 had high MS instability.

The median follow-up was 14.3 months. Seven patients had a confirmed partial response: 3 with MSS, 3 with unknown MSS status, and 1 with low MS instability. The median duration of response was 14.8 months.

Less than one-third (31%) of patients had a partial response or stable disease. The median progression-free survival was 1.9 months; median overall survival was 10 months.

Treatment-related grade 3 to 4 adverse events were noted in 37% of patients.

The authors concluded that the combination “demonstrated a tolerable safety profile and improvements in [overall survival] vs those reported with [standard of care] in heavily pretreated [patients] with [metastatic] CRC.”

Read more of Cancer Therapy Advisor's coverage of the 2018 Gastrointestinal Cancers Symposium by visiting the conference page.

Reference

  1. Bendell JC, Bang YJ, Chee CE, et al. A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC). Oral presentation at: 2018 Gastrointestinal Cancers Symposium; January 18-20, 2018; San Francisco, CA.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs